
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31703647</article-id><article-id pub-id-type="pmc">6839052</article-id><article-id pub-id-type="publisher-id">6285</article-id><article-id pub-id-type="doi">10.1186/s12885-019-6285-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sun</surname><given-names>Yun-Chuan</given-names></name><address><email>doctorsunyc@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bi</surname><given-names>Jian-Qiang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Xin-Ying</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Radiation Oncology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, 061000 Hebei China </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>19</volume><elocation-id>1063</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Prostate cancer is one of the most common cancers in the world. The results of treatment after hypofractionated radiotherapy only have been reported from several small randomized clinical trials. Therefore, we conducted a meta-analysis to compare clinical outcomes of hypofractionated radiotherapy versus conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer.</p></sec><sec><title>Methods</title><p id="Par2">Relevant studies were identified through searching related databases till August 2018. Hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) was used as pooled statistics for all analyses.</p></sec><sec><title>Results</title><p id="Par3">The meta-analysis results showed that overall survival (HR&#x02009;=&#x02009;1.12, 95% CI: 0.93&#x02013;1.35, <italic>p</italic>&#x02009;=&#x02009;0.219) and prostate cancer-specific survival (HR&#x02009;=&#x02009;1.29, 95% CI: 0.42&#x02013;3.95, <italic>p</italic>&#x02009;=&#x02009;0.661) were similar in two groups. The pooled data showed that biochemical failure was RR&#x02009;=&#x02009;0.90, 95% CI: 0.76&#x02013;1.07, <italic>p</italic>&#x02009;=&#x02009;0.248. The incidence of acute adverse gastrointestinal events (grade&#x02009;&#x02265;&#x02009;2) was higher in the hypofractionated radiotherapy (RR&#x02009;=&#x02009;1.70, 95% CI: 1.12&#x02013;2.56, <italic>p</italic>&#x02009;=&#x02009;0.012); conversely, for late grade&#x02009;&#x02265;&#x02009;2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found (RR&#x02009;=&#x02009;0.75, 95% CI: 0.61&#x02013;0.91, <italic>p</italic>&#x02009;=&#x02009;0.003). Acute (RR&#x02009;=&#x02009;1.01, 95% CI: 0.89&#x02013;1.15, <italic>p</italic>&#x02009;=&#x02009;0.894) and late (RR&#x02009;=&#x02009;0.98, 95% CI: 0.86&#x02013;1.10, <italic>p</italic>&#x02009;=&#x02009;0.692) genitourinary adverse events (grade&#x02009;&#x02265;&#x02009;2) were similar for both treatment groups.</p></sec><sec><title>Conclusion</title><p id="Par4">Results suggest that the efficacy and risk for adverse events are comparable for hypofractionated radiotherapy and conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Hypofractionated radiotherapy</kwd><kwd>Conventional radiotherapy</kwd><kwd>Efficacy</kwd><kwd>Adverse event</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par15">Prostate cancer (PCa) is one of the most common cancers in the world, especially in North America and Western Europe [<xref ref-type="bibr" rid="CR1">1</xref>], with over 50% of patients suffering from intermediate- to high-risk localized PCa [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. On the basis of the results of previous studies, external-beam radiation therapy (EBRT) combined with androgen deprivation therapy (ADT) is a standard treatment for patients with intermediate- to high-risk PCa [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Compared with a dose of 75.6 to 79.2Gy for low-risk patients, doses up to 81Gy in form of conventional fractionation schedules have been recommended for patients with intermediate- to high-risk PCa [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. However, conventionally fractionated dose escalation protracts treatment time, which could possibly increase side effects and yield lower treatment efficacy.</p><p id="Par16">In ideal conditions, radiotherapy dose fractionation schedules should take into account the sensitivity to radiation of the tumor relative to nearby non-tumor tissues. Accumulating evidence shows that the &#x003b1;/&#x003b2; ratio for PCa is low and range from 0.9 to 2.2&#x02009;Gy [<xref ref-type="bibr" rid="CR9">9</xref>]. Radiobiological theory suggests that hypofractionated radiation schedules applied in fewer fractions and with larger single doses could increase treatment effects [<xref ref-type="bibr" rid="CR10">10</xref>]. Further, hypofractionated radiotherapy with single dose&#x02265;2.5&#x02009;Gy per fraction could theoretically maintain high biologically effective doses, while not increasing acute and late adverse events, but efficiently shortening the treatment time. Such outcome would translate into higher treatment capacity and could potentially reduce treatment cost [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par17">The results of treatment after hypofractionated radiotherapy have only been reported from several small randomized trials [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The efficacy and adverse events of hypofractionated radiotherapy seemed to be comparable with conventional schedules in the treatment of intermediate- to high-risk PCa. However, small sample size trials might have biased results, although no significant effect of publication bias was detected. Lastly, we pooled the relevant outcomes of randomized trials and compared the efficacy and adverse events profile of hypofractionated with those of conventional radiotherapy for intermediate- to high-risk localized PCa.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Literature search</title><p id="Par18">This meta-analysis was conducted according to Preferred Reporting Items For Systematic Reviews and Meta-analyses guidelines (PRISMA) [<xref ref-type="bibr" rid="CR14">14</xref>]. As this meta-analysis was performed based on the published data, ethics committee and/or institutional board approval was not required. Our literature search was performed via Pubmed, Embase and Web of Science databases. The last search was updated to August 2018. The search strategy was: &#x0201c;prostatic neoplasms&#x0201d; (MeSH Terms), &#x0201c;radiotherapy&#x0201d; (MeSH Terms), and &#x0201c;hypofractionated&#x0201d; (All Fields). At the same time, we also checked abstracts published in major academic conferences. The references of studies included were screened to locate potentially eligible articles.</p></sec><sec id="Sec4"><title>Study selection</title><p id="Par19">The selected studies should meet the following eligibility criteria: (1) comparison of the use of hypofractionated (ie, dose per fraction range from 2.4&#x02013;4.0&#x02009;Gy) with that of conventional radiotherapy (1.8&#x02013;2.0&#x02009;Gy per fraction) for intermediate- to high-risk PCa; (2) clear description of applied case selection criteria; (3) reported data allows calculating hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) or alternatively these could be computed according to Tierney&#x02019;s method [<xref ref-type="bibr" rid="CR15">15</xref>]; (4) published as full-text articles; (5) published in English language. The exclusion criteria were: (1) patients have received previous pelvic radiotherapy or radical prostatectomy; (2) animal studies; (4) letters, conference abstracts or review articles.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par20">Two investigators (W.G. And L.X.) independently extracted the following data from the eligible studies using a predefined protocol: name of the first author, country, sample size, radiotherapy methods, radiotherapy schedule, androgen deprivation therapy (ADT) and clinical outcome measures. Discrepancies between the two reviewers were settled by the third investigator (Y.C.S. and X.Y.H.).</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par21">HRs and RRs with 95% CIs for clinical outcome measures were directly obtained from each study if available or were calculated from raw data using the method reported by Tierney et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. The Cochran&#x02019;s Q test and Higgins I-squared statistic were used to evaluate the heterogeneity of pooled results. If I<sup>2</sup> &#x0003e;50% and P for heterogeneity &#x0003c;&#x02009;0.1, which show significant heterogeneity, the random-effect model was used; otherwise, the fixed-effects model was conducted. Sensitivity analyses were performed to evaluate the impact of individual studies on the overall estimate. Begg&#x02019;s funnel plot was assessed to find publication bias. All data were analyzed through the STATA 12.0 software (Stata Corp, College Station, TX, USA). A <italic>p</italic>-value &#x0003c;&#x02009;0.05 was considered as statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Study characteristics</title><p id="Par22">A total of 416 articles were initially identified. Duplicates were removed and 364 articles remained. A total of 316 records were excluded after titles and abstracts screening. Full texts and data integrity were then reviewed, and another 36 papers were excluded. In the end, 12 studies (6 cohorts) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>] were included in the final meta-analysis. Our article selection process is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. All the studies included were randomized controlled trials. Publication years of the records included articles from 2006 to 2017. A total of 2827 patients consisting of 1444 cases treated with hypofractionated radiotherapy and 1383 cases treated with conventional radiotherapy from 6 cohorts were included for this meta-analysis. All patients suffered from intermediate- to high-risk PCa and did not receive previous pelvic radiotherapy or radical prostatectomy. Three cohorts were from Italy, one from the USA and one from Netherlands. The latest study was conducted in 27 centers (14 in Canada, 12 in Australia, and one in France). The detailed characteristics of the selected studies are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of the included trials</p></caption><graphic xlink:href="12885_2019_6285_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Study characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Year</th><th>Country</th><th>n</th><th>TNM or risk group</th><th>RT</th><th>Design</th><th>Schedule</th><th>ADT</th><th>Outcomes</th></tr></thead><tbody><tr><td rowspan="2">Aluwini et al</td><td rowspan="2">2015&#x02013;2016</td><td rowspan="2">Netherlands</td><td>410</td><td rowspan="2"><p>T<sub>1b</sub>-T<sub>4</sub>N<sub>X-0</sub>M<sub>X-0</sub></p><p>intermediate- to high-risk</p></td><td rowspan="2">Most IMRT</td><td rowspan="2">Hypofractionated versus conventional</td><td>64.6Gy (19 fractions within 6.5wks)</td><td rowspan="2">Yes</td><td rowspan="2"><p>OS, BF</p><p>acute and late adverse events</p></td></tr><tr><td>410</td><td>78Gy (39 fractions within 8wks)</td></tr><tr><td rowspan="2">Arcangeli et al</td><td rowspan="2">2010&#x02013;2017</td><td rowspan="2">Italy</td><td>83</td><td rowspan="2"><p>&#x02265;T<sub>2c</sub>, Gleason &#x02265;7</p><p>PSA &#x02265;20ng/ml</p><p>high-risk</p></td><td rowspan="2">3D-CRT</td><td rowspan="2">Hypofractionated versus conventional</td><td>62Gy (20 fractions of 3.1Gy, 5wks)</td><td rowspan="2">Yes</td><td rowspan="2"><p>OS, BF, PCaSS</p><p>acute and late adverse events</p></td></tr><tr><td>85</td><td>80Gy (40 fractions of 2Gy, 8wks)</td></tr><tr><td rowspan="2">Pollack et al</td><td rowspan="2">2007&#x02013;2013</td><td rowspan="2">US</td><td>154</td><td rowspan="2"><p>T<sub>1</sub>-T<sub>3</sub>, Gleason &#x02265;5</p><p>intermediate- to high-risk</p></td><td rowspan="2">IMRT</td><td rowspan="2">Hypofractionated versus conventional</td><td>70.2Gy (26 fractions of 2.7Gy)</td><td rowspan="2">Yes</td><td rowspan="2"><p>OS, BF</p><p>late adverse event</p></td></tr><tr><td>153</td><td>76Gy (38 fractions of 2Gy)</td></tr><tr><td rowspan="2">Marzi et al</td><td rowspan="2">2009</td><td rowspan="2">Italy</td><td>57</td><td rowspan="2"><p>&#x02265;T<sub>2c</sub>, Gleason7-10</p><p>PSA&#x0003e;10ng/ml</p><p>high-risk</p></td><td rowspan="2">3D-CRT</td><td rowspan="2">Hypofractionated versus conventional</td><td>62Gy (20 fractions of 3.1Gy)</td><td rowspan="2">Yes</td><td rowspan="2">late adverse event</td></tr><tr><td>57</td><td>80Gy (40 fractions of 2Gy)</td></tr><tr><td rowspan="4">Strigary et al</td><td rowspan="4">2009</td><td rowspan="4">Italy</td><td>80</td><td rowspan="4">localized prostate cancer high-risk</td><td rowspan="4">3D-CRT</td><td rowspan="4">Hypofractionated versus conventional</td><td>62Gy (20 fractions of 3.1Gy)</td><td rowspan="4">Yes</td><td rowspan="4">acute adverse event</td></tr><tr><td rowspan="2">52</td><td>56Gy (16 fractions of 3.5Gy)</td></tr><tr><td rowspan="2">80Gy (40 fractions of 2Gy, 8wks)</td></tr><tr><td>80</td></tr><tr><td rowspan="3">Catton et al</td><td rowspan="3">2017</td><td>Canada</td><td rowspan="2">608</td><td rowspan="3">intermediate-risk</td><td rowspan="3">IMRT</td><td rowspan="3">Hypofractionated versus conventional</td><td rowspan="2">60Gy (20 fractions of 3Gy)</td><td rowspan="3">Yes</td><td rowspan="3"><p>BF, PCaSS</p><p>acute and late adverse events</p></td></tr><tr><td>Australia</td></tr><tr><td>France</td><td>598</td><td>78Gy (39 fractions of 2Gy)</td></tr></tbody></table><table-wrap-foot><p><italic>OS</italic> Overall survival, <italic>BF</italic> Biochemical failure, <italic>ADT</italic> Androgen deprivation therapy, <italic>PCaSS</italic> Prostate cancer-specific survival, <italic>IMRT</italic> Intensity-modulated radiation therapy, <italic>3D-CRT</italic> Three-dimensional conformal radiotherapy, <italic>PSA</italic> Prostate-specific antigen</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Overall survival, prostate cancer-specific survival and biochemical failure</title><p id="Par23">Because of homogeneous outcomes of the selected studies (I<sup>2</sup>&#x000a0;=&#x02009;0, <italic>p</italic>&#x02009;=&#x02009;0.606), the fixed-effect model was applied for the overall survival (OS) rate. Our results showed that hypofractionated radiotherapy was not superior to conventional radiotherapy (HR&#x02009;=&#x02009;1.12, 95% CI: 0.93&#x02013;1.35, <italic>p</italic>&#x02009;=&#x02009;0.219, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). The hypofractionated radiotherapy and the conventional radiotherapy of patients showed no substantial differences in prostate cancer-specific survival analysis (HR&#x02009;=&#x02009;1.29, 95% CI: 0.42&#x02013;3.95, <italic>p</italic>&#x02009;=&#x02009;0.661) and showed a high level of heterogeneity based on the random effect model (I<sup>2</sup>&#x000a0;=&#x02009;61.6%, <italic>p</italic>&#x02009;=&#x02009;0.106, Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). We used a fixed-effect model to analyze biochemical failure (BF) because there was no statistical heterogeneity across studies (I<sup>2</sup>&#x000a0;=&#x02009;0, <italic>p</italic>&#x02009;=&#x02009;0.440), and the number of patients who were affected by BF was similar among the two groups (RR&#x02009;=&#x02009;0.90, 95% CI: 0.76&#x02013;1.07, <italic>p</italic>&#x02009;=&#x02009;0.248, Fig. <xref rid="Fig2" ref-type="fig">2</xref>c).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Forest plot for overall survival (<bold>a</bold>), prostate cancer-specific survival (<bold>b</bold>) and biochemical failure (<bold>c</bold>)</p></caption><graphic xlink:href="12885_2019_6285_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec10"><title>Acute and late adverse events</title><p id="Par24">The incidence of grade 2 or worse acute adverse gastrointestinal events were analyzed by the random effect model due to heterogeneous outcomes (I<sup>2</sup>&#x000a0;=&#x02009;67.2%, <italic>p</italic>&#x02009;=&#x02009;0.016) and the pooled data revealed a clear rising trend in the hypofractionated radiotherapy compared with conventional radiotherapy (RR&#x02009;=&#x02009;1.70, 95% CI: 1.12&#x02013;2.56, <italic>p</italic>&#x02009;=&#x02009;0.012, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). However, acute grade&#x02009;&#x02265;&#x02009;3 adverse gastrointestinal events were not significantly different between groups (<italic>p</italic>&#x0003e;0.05). Acute genitourinary adverse events (grade&#x02009;&#x02265;&#x02009;2) were similar among the groups (RR&#x02009;=&#x02009;1.01, 95% CI: 0.89&#x02013;1.15, <italic>p</italic>&#x02009;=&#x02009;0.894, Fig. <xref rid="Fig3" ref-type="fig">3</xref>b) with no heterogeneity (I<sup>2</sup>&#x000a0;=&#x02009;0, <italic>p</italic>&#x02009;=&#x02009;0.683).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Forest plot for acute adverse gastrointestinal event (<bold>a</bold>), acute genitourinary adverse event (<bold>b</bold>), late adverse gastrointestinal event (<bold>c</bold>) and late adverse genitourinary event (<bold>d</bold>)</p></caption><graphic xlink:href="12885_2019_6285_Fig3_HTML" id="MO3"/></fig></p><p id="Par25">Analysis by the fixed-effect model (I<sup>2</sup>&#x000a0;=&#x02009;0, <italic>p</italic>&#x02009;=&#x02009;0.826) showed that conventional radiotherapy significantly increased the grade&#x02009;&#x02265;&#x02009;2 late gastrointestinal adverse event in comparison with the hypofractionated radiotherapy (RR&#x02009;=&#x02009;0.75, 95% CI: 0.61&#x02013;0.91, <italic>p</italic>&#x02009;=&#x02009;0.003, Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). The grade&#x02009;&#x02265;&#x02009;2 late genitourinary adverse event data were similar between the hypofractionated radiotherapy and conventional radiotherapy groups (RR&#x02009;=&#x02009;0.98, 95% CI: 0.86&#x02013;1.10, <italic>p</italic>&#x02009;=&#x02009;0.692, Fig. <xref rid="Fig3" ref-type="fig">3</xref>d) and no heterogeneity was found for this analysis (I<sup>2</sup>&#x000a0;=&#x02009;0, <italic>p</italic>&#x02009;=&#x02009;0.496).</p></sec><sec id="Sec11"><title>Subgroup analysis</title><p id="Par26">When we analyzed the subgroup of patients who received only conventional higher doses of radiotherapy (&#x02265;78&#x02009;Gy) versus hypofractionated radiotherapy, the incidence of grade 2 or worse acute adverse gastrointestinal events were still higher in the hypofractionated radiotherapy (RR&#x02009;=&#x02009;1.66, 95% CI: 1.05&#x02013;2.61, <italic>p</italic>&#x02009;=&#x02009;0.029). However, the other results (OS, BF and genitourinary adverse events etc.) were not significantly different between the two groups (all <italic>p</italic>&#x0003e;0.05).</p></sec><sec id="Sec12"><title>Sensitivity analysis and publication bias</title><p id="Par27">Sensitivity analysis was performed to demonstrate whether the meta-analysis result was robust. The results of sensitivity analysis were shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, which revealed that no individual studies affected the pooled HR or RR significantly, showing a statistically stability result. Begg test demonstrated no significant statistical evidence of publication bias (<italic>p</italic>&#x0003e;0.05), which suggested that this meta-analysis was not significantly affected by publication bias.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Sensitivity analysis of late adverse genitourinary event</p></caption><graphic xlink:href="12885_2019_6285_Fig4_HTML" id="MO4"/></fig></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par28">A large number of clinical studies have suggested that dose escalation is associated with improved biochemical and OS outcomes [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. A study of the National Cancer Data Base showed that dose escalation resulted in an improvement in OS for patients with intermediate- to high-risk PCa [<xref ref-type="bibr" rid="CR30">30</xref>]. Kuban et al. [<xref ref-type="bibr" rid="CR29">29</xref>] published their dose-escalation study of 301 patients with T<sub>1b</sub> to T<sub>3</sub> PCa. Clinical failure or freedom from biochemical was superior for patients treated with 78Gy versus 70Gy (78% vs. 59%, <italic>p</italic>&#x02009;=&#x02009;0.004), and the patients with initial prostate specific antigen (PSA)&#x0003e;10&#x02009;ng/ml (intermediate- to high-risk PCa) had a greater benefit (78% vs. 39%, <italic>p</italic>&#x02009;=&#x02009;0.001). However, conventionally fractionated dose escalation increased toxicity and overall treatment time. With improved radiotherapy technologies, hypofractionated radiotherapy plays a crucial role in the treatment of intermediate- to high-risk PCa. Several randomized trials have proved that efficacy and adverse events of hypofractionated radiotherapy were similar to conventional radiotherapy in most [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] but not all trials [<xref ref-type="bibr" rid="CR18">18</xref>]. With aims to provide sufficient evidence for clarifying the discrepancies, the present meta-analysis was designed to compare clinical outcomes and adverse events of hypofractionated radiotherapy with conventional radiotherapy for patients with intermediate- to high-risk PCa with the aim to increase the precision of the comparisons and the estimate of treatment benefit.</p><p id="Par29">Overall survival is the most important result for any cancer therapy because it accounts for secondary mortality causes, the interventions used, and all other mortality causes. Given the indolent nature of the progression of prostate cancer, long-term follow-up is of particular importance to assess differences in overall survival [<xref ref-type="bibr" rid="CR31">31</xref>]. The median follow-up for the selected studies ranges from 5 to 9&#x02009;years, and we found that hypofractionated radiotherapy was not superior to conventional radiotherapy. Although hypofractionated radiotherapy did not significantly improve overall survival, it enhanced biological efficacy of delivered radiation dose and reduced overall treatment time, presumably making the treatment more acceptable for patients. Biochemical failure was defined according to the Phoenix definition of nadir PSA plus 2&#x02009;ng/ml [<xref ref-type="bibr" rid="CR32">32</xref>]. Although there was no significant difference in avoiding biochemical failure between the two groups, there was still a trend in favor of hypofractionated radiotherapy. The &#x003b1;/&#x003b2; ratio for PCa is 1.5Gy from the included studies. After further analysis, we found that the biologically effective dose (BED) of hypofractionated radiotherapy was slightly higher compared to conventional radiotherapy. This difference may explain why no significant difference in biochemical failure was detected between groups.</p><p id="Par30">Recently, hypofractionated radiotherapy has been introduced as treatment for prostate cancer. Noteworthy, hypofractionated radiotherapy schedules have a large variability in the treatment regimens, and the data on adverse events are sparse. Thus, we pooled the relevant data and found the incidence of acute adverse gastrointestinal event (grade&#x02009;&#x02265;&#x02009;2) was higher in the hypofractionated radiotherapy; conversely, for late grade&#x02009;&#x02265;&#x02009;2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found. Furthermore, grade&#x02009;&#x02265;&#x02009;3 acute gastrointestinal adverse events in the two groups was not significantly different, and grade 2 acute gastrointestinal adverse events were acceptable for patients. The BED for acute gastrointestinal effect for hypofractionated radiotherapy was significantly greater compared to conventional radiotherapy in the included trials evaluated for acute gastrointestinal toxicity (<italic>p&#x0003c;</italic>0.05). This could be expected to contribute to the increased acute toxicity with hypofractionated radiotherapy. The reduction in late adverse event for hypofractionated radiotherapy is consistent with the linear-quadratic model by Catton et al. [<xref ref-type="bibr" rid="CR25">25</xref>] that would predict a lower biologically equivalent dose for normal tissues with an &#x003b1;/&#x003b2; of 3-5Gy. This finding is further supported by the trial conducted by Dearnaley et al. [<xref ref-type="bibr" rid="CR33">33</xref>], who reported a lower 5-year incidence of grade&#x02009;&#x02265;&#x02009;2 gastrointestinal adverse events for both hypofractionated groups compared to conventional therapy.</p><p id="Par31">Our pooled data showed that Grade&#x02009;&#x02265;&#x02009;2 acute and late genitourinary adverse events were not significantly different between the groups. In 2016, another meta-analysis from Cao et al. found similar genitourinary adverse events between hypofractionated and conventional groups [<xref ref-type="bibr" rid="CR34">34</xref>]. A long-term late adverse event finding from Arcangeli et al. showed that, a relevant impact did not appear with high-dose fractions and; significant differences were only seen for minor (grade 1), late genitourinary adverse events, namely, for macroscopic hematuria [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par32">Our meta-analysis was the first designed to compare clinical outcomes and adverse events between hypofractionated radiotherapy and conventional radiotherapy for the treatment of intermediate- to high-risk localized PCa. In terms of efficacy and adverse events, a large number of studies had tested hypofractionated radiotherapy and found that effects were compared to conventional radiotherapy in the treatment of low-risk localized PCa [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. Published meta-analyses suggest that hypofractionated radiotherapy could result in comparable therapeutic effects for patients suffering from localized prostate cancer without increasing the rate of acute or late adverse events of the gastrointestinal or genitourinary system [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. Our results are in accordance with these previous findings.</p><p id="Par33">Noteworthy, the current meta-analysis had a number of limitations. First, the patients included in our meta-analysis were all Caucasian ethnicity. Therefore, the conclusions of this study should be treated with caution when applied on other ethnic populations. Second, we failed to analyze the absence of biochemical failure because the reported data was insufficient. Third, the heterogeneity of acute gastrointestinal adverse events was relatively large, which might affect its result.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par34">In summary, meta-analytical data suggest that the efficacy of hypofractionated radiotherapy is comparable to conventional radiotherapy in the treatment of intermediate- to high-risk localized PCa. Although incidences of acute gastrointestinal adverse events were found higher for patients treated with hypofractionated radiotherapy, hypofractionated radiotherapy was safe with overall acceptable adverse event rates. However, due to the limited sample of trials that informed this meta-analysis, these findings should be utilized cautiously when directed in clinical treatment.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADT</term><def><p id="Par5">Androgen deprivation therapy</p></def></def-item><def-item><term>BF</term><def><p id="Par6">Biochemical failure</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>EBRT</term><def><p id="Par8">External-beam radiation therapy</p></def></def-item><def-item><term>HR</term><def><p id="Par9">Hazard ratio</p></def></def-item><def-item><term>OS</term><def><p id="Par10">Overall survival</p></def></def-item><def-item><term>PCa</term><def><p id="Par11">Prostate cancer</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par12">Preferred Reporting Items For Systematic Reviews and Meta-analyses</p></def></def-item><def-item><term>PSA</term><def><p id="Par13">Prostate specific antigen</p></def></def-item><def-item><term>RR</term><def><p id="Par14">Risk ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>WG and Y-CS designed the research; WG and J-QB performed the experiments; X-YH and LX provided analyzed the data; WG wrote the manuscript. All authors have read and approved the manuscript and ensure that this is the case.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data are available from the references provided.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par35">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par36">All data are based on published research and are subject to copyright agreements.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><issue>2</issue><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>NA</given-names></name><name><surname>Anscher</surname><given-names>MS</given-names></name></person-group><article-title>Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations</article-title><source>Oncology (Williston Park)</source><year>2016</year><volume>30</volume><issue>3</issue><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">26984216</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>FB</given-names></name><name><surname>Mikkelsen</surname><given-names>MK</given-names></name><name><surname>Hansen</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center</article-title><source>Acta Oncol</source><year>2016</year><volume>55</volume><issue>12</issue><fpage>1456</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2016.1191667</pub-id><pub-id pub-id-type="pmid">27333339</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>AV</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Renshaw</surname><given-names>A</given-names></name><name><surname>Loffredo</surname><given-names>M</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name></person-group><article-title>Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer</article-title><source>JAMA</source><year>2015</year><volume>314</volume><issue>12</issue><fpage>1291</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.8577</pub-id><pub-id pub-id-type="pmid">26393854</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisansky</surname><given-names>TM</given-names></name><name><surname>Hunt</surname><given-names>D</given-names></name><name><surname>Gomella</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>4</issue><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.0662</pub-id><pub-id pub-id-type="pmid">25534388</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Rossi</surname><given-names>PJ</given-names></name><name><surname>Jani</surname><given-names>AB</given-names></name></person-group><article-title>Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer</article-title><source>Am J Clin Oncol</source><year>2011</year><volume>34</volume><issue>1</issue><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1097/COC.0b013e3181cae8c6</pub-id><pub-id pub-id-type="pmid">20101167</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelefsky</surname><given-names>MJ</given-names></name><name><surname>Levin</surname><given-names>EJ</given-names></name><name><surname>Hunt</surname><given-names>M</given-names></name><etal/></person-group><article-title>Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>70</volume><issue>4</issue><fpage>1124</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.11.044</pub-id><pub-id pub-id-type="pmid">18313526</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eade</surname><given-names>TN</given-names></name><name><surname>Hanlon</surname><given-names>AL</given-names></name><name><surname>Horwitz</surname><given-names>EM</given-names></name><name><surname>Buyyounouski</surname><given-names>MK</given-names></name><name><surname>Hanks</surname><given-names>GE</given-names></name><name><surname>Pollack</surname><given-names>A</given-names></name></person-group><article-title>What dose of external-beam radiation is high enough for prostate cancer?</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>68</volume><issue>3</issue><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.01.008</pub-id><pub-id pub-id-type="pmid">17398026</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miralbell</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Zubizarreta</surname><given-names>E</given-names></name><name><surname>Hendry</surname><given-names>JH</given-names></name></person-group><article-title>Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>82</volume><issue>1</issue><fpage>e17</fpage><lpage>e24</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.10.075</pub-id><pub-id pub-id-type="pmid">21324610</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>EF</given-names></name><name><surname>Lee</surname><given-names>WR</given-names></name></person-group><article-title>Hypofractionation for prostate cancer: a critical review</article-title><source>Semin Radiat Oncol</source><year>2008</year><volume>18</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.semradonc.2007.09.006</pub-id><pub-id pub-id-type="pmid">18082587</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupelian</surname><given-names>PA</given-names></name><name><surname>Reddy</surname><given-names>CA</given-names></name><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Willoughby</surname><given-names>TR</given-names></name></person-group><article-title>Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>51</volume><issue>4</issue><fpage>988</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(01)01730-8</pub-id><pub-id pub-id-type="pmid">11704322</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcangeli</surname><given-names>G</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Gomellini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>79</volume><issue>4</issue><fpage>1013</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.12.045</pub-id><pub-id pub-id-type="pmid">20447774</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>G</given-names></name><name><surname>Horwitz</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>31</issue><fpage>3860</fpage><lpage>3868</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.51.1972</pub-id><pub-id pub-id-type="pmid">24101042</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><etal/></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>4</issue><fpage>W65</fpage><lpage>W94</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00136</pub-id><pub-id pub-id-type="pmid">19622512</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tierney</surname><given-names>JF</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Burdett</surname><given-names>S</given-names></name><name><surname>Sydes</surname><given-names>MR</given-names></name></person-group><article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title><source>Trials</source><year>2007</year><volume>8</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-8-16</pub-id><pub-id pub-id-type="pmid">17555582</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Incrocci</surname><given-names>L</given-names></name><name><surname>Wortel</surname><given-names>RC</given-names></name><name><surname>Alemayehu</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><issue>8</issue><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30070-5</pub-id><pub-id pub-id-type="pmid">27339116</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluwini</surname><given-names>S</given-names></name><name><surname>Pos</surname><given-names>F</given-names></name><name><surname>Schimmel</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><issue>4</issue><fpage>464</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00567-7</pub-id><pub-id pub-id-type="pmid">26968359</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluwini</surname><given-names>S</given-names></name><name><surname>Pos</surname><given-names>F</given-names></name><name><surname>Schimmel</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>3</issue><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70482-6</pub-id><pub-id pub-id-type="pmid">25656287</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcangeli</surname><given-names>G</given-names></name><name><surname>Saracino</surname><given-names>B</given-names></name><name><surname>Gomellini</surname><given-names>S</given-names></name><etal/></person-group><article-title>A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>78</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.07.1691</pub-id><pub-id pub-id-type="pmid">20047800</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcangeli</surname><given-names>S</given-names></name><name><surname>Strigari</surname><given-names>L</given-names></name><name><surname>Gomellini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>84</volume><issue>5</issue><fpage>1172</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.02.049</pub-id><pub-id pub-id-type="pmid">22537541</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcangeli</surname><given-names>G</given-names></name><name><surname>Saracino</surname><given-names>B</given-names></name><name><surname>Arcangeli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>17</issue><fpage>1891</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.70.4189</pub-id><pub-id pub-id-type="pmid">28355113</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>Hanlon</surname><given-names>AL</given-names></name><name><surname>Horwitz</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>64</volume><issue>2</issue><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.07.970</pub-id><pub-id pub-id-type="pmid">16242256</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzi</surname><given-names>S</given-names></name><name><surname>Saracino</surname><given-names>B</given-names></name><name><surname>Petrongari</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer</article-title><source>J Exp Clin Cancer Res</source><year>2009</year><volume>28</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-28-117</pub-id><pub-id pub-id-type="pmid">19689825</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strigari</surname><given-names>L</given-names></name><name><surname>Arcangeli</surname><given-names>G</given-names></name><name><surname>Arcangeli</surname><given-names>S</given-names></name><name><surname>Benassi</surname><given-names>M</given-names></name></person-group><article-title>Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2009</year><volume>73</volume><issue>5</issue><fpage>1454</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.07.024</pub-id><pub-id pub-id-type="pmid">18990503</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catton</surname><given-names>CN</given-names></name><name><surname>Lukka</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Randomized trial of a Hypofractionated radiation regimen for the treatment of localized prostate cancer</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>17</issue><fpage>1884</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.7397</pub-id><pub-id pub-id-type="pmid">28296582</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>ST</given-names></name><name><surname>Heemsbergen</surname><given-names>WD</given-names></name><name><surname>Koper</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>13</issue><fpage>1990</fpage><lpage>1996</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.2530</pub-id><pub-id pub-id-type="pmid">16648499</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dearnaley</surname><given-names>DP</given-names></name><name><surname>Jovic</surname><given-names>G</given-names></name><name><surname>Syndikus</surname><given-names>I</given-names></name><etal/></person-group><article-title>Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>4</issue><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70040-3</pub-id><pub-id pub-id-type="pmid">24581940</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denham</surname><given-names>JW</given-names></name><name><surname>Steigler</surname><given-names>A</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><etal/></person-group><article-title>Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial</article-title><source>Radiother Oncol</source><year>2015</year><volume>115</volume><issue>3</issue><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2015.05.016</pub-id><pub-id pub-id-type="pmid">26072289</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuban</surname><given-names>DA</given-names></name><name><surname>Tucker</surname><given-names>SL</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>70</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.06.054</pub-id><pub-id pub-id-type="pmid">17765406</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer</article-title><source>JAMA Oncol</source><year>2015</year><volume>1</volume><issue>7</issue><fpage>897</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.2316</pub-id><pub-id pub-id-type="pmid">26181727</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>SC</given-names></name><name><surname>Waldron</surname><given-names>TS</given-names></name><name><surname>Eapen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis</article-title><source>Radiother Oncol</source><year>2008</year><volume>88</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2008.04.013</pub-id><pub-id pub-id-type="pmid">18501455</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>M</given-names><suffix>3rd</suffix></name><name><surname>Hanks</surname><given-names>G</given-names></name><name><surname>Thames</surname><given-names>H</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>65</volume><issue>4</issue><fpage>965</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.04.029</pub-id><pub-id pub-id-type="pmid">16798415</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dearnaley</surname><given-names>D</given-names></name><name><surname>Syndikus</surname><given-names>I</given-names></name><name><surname>Mossop</surname><given-names>H</given-names></name><etal/></person-group><article-title>Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><issue>8</issue><fpage>1047</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30102-4</pub-id><pub-id pub-id-type="pmid">27339115</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>ZW</given-names></name><etal/></person-group><article-title>Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>2</issue><fpage>2647</fpage><lpage>2658</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13735</pub-id><pub-id pub-id-type="pmid">27926521</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeriani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients</article-title><source>J Biomed Biotechnol</source><year>2014</year><volume>2014</volume><fpage>465175</fpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeriani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Moderate hypofractionation in patients with low-risk prostate cancer: long-term outcomes</article-title><source>Anticancer Res</source><year>2018</year><volume>38.3</volume><fpage>1671</fpage><pub-id pub-id-type="pmid">29491101</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Bruner DW, et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA Oncol, Epub ahead of print. 2019.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>ZZ</given-names></name><name><surname>You</surname><given-names>JQ</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from phase III randomized trials</article-title><source>Onco Targets Ther</source><year>2019</year><volume>12</volume><fpage>1259</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.2147/OTT.S181067</pub-id><pub-id pub-id-type="pmid">30863093</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>&#x000cd;T</given-names></name><name><surname>Baccaglini</surname><given-names>W</given-names></name><name><surname>Claros</surname><given-names>OR</given-names></name><etal/></person-group><article-title>Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis</article-title><source>Acta Oncol</source><year>2018</year><volume>57</volume><issue>8</issue><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2018.1478126</pub-id><pub-id pub-id-type="pmid">29882448</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez-G&#x000f3;mez</surname><given-names>LM</given-names></name><name><surname>Polo-deSantos</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez-Melc&#x000f3;n</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Hypofractionated radiation therapy versus conventional radiation therapy in prostate cancer: a systematic review of its safety and efficacy</article-title><source>Actas Urol Esp</source><year>2015</year><volume>39</volume><issue>6</issue><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.acuro.2014.12.005</pub-id><pub-id pub-id-type="pmid">25660427</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botrel</surname><given-names>TE</given-names></name><name><surname>Clark</surname><given-names>O</given-names></name><name><surname>Pompeo</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis</article-title><source>Core Evid</source><year>2013</year><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.2147/CE.S41178</pub-id><pub-id pub-id-type="pmid">23526383</pub-id></element-citation></ref></ref-list></back></article>